Search the Newsreel

RELL|Richardson Electronics Ltd|Price:16.700|Chg%:-2.060

The article provides a comprehensive stock analysis of Richardson Electronics Ltd (RELL) by TradingKey, highlighting its strong fundamentals and high growth potential. The company's valuation is considered fairly valued within its industry, with high institutional ownership. Analysts have rated RELL as a "Buy" with …

What To Expect From Perella Weinberg’s (PWP) Q2 Earnings

What To Expect From Perella Weinberg's (PWP) Q2 Earnings Financial advisory firm Perella Weinberg Partners (NASDAQ:PWP) will be reporting earnings this Friday morning. Here's what you need to know. Perella Weinberg missed analysts' revenue expectations last quarter, reporting revenues of $148.9 million, down 29.7% …

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma announced the activation of Baylor Scott & White Research Institute as the second clinical site for its Phase I/II STARLIGHT-1 trial. This trial evaluates EB103, a CD19-Redirected ARTEMIS® T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). The expansion …

Estrella Immunopharma, Inc. Revenue Breakdown – NASDAQ:ESLAW

This article provides a basic overview of Estrella Immunopharma, Inc. (NASDAQ: ESLAW) financial information available on TradingView, focusing on its revenue breakdown. It indicates that further details regarding segment and regional performance by source and country can be accessed through the platform. The content …

Estrella activates second site for EB103 lymphoma trial By Investing.com

Estrella Immunopharma, Inc. has activated a second clinical site, Baylor Scott & White Research Institute, for its STARLIGHT-1 Phase I/II trial evaluating EB103 for relapsed or refractory B-cell non-Hodgkin’s lymphoma. This expansion aims to broaden the trial's reach and gather more data to determine …

Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Estrella Immunopharma Inc (ESLA), focusing on its PE, PB, and fair value. It includes current stock performance metrics and links to further financial data and company overviews.

AMBA|Ambarella Inc|Price:68.970|Chg%:+0.740

This article provides an in-depth analysis of Ambarella Inc (AMBA), detailing its market trends, real-time quotes, and trading strategies. It highlights the company's strong fundamentals, high growth potential, and positive analyst ratings, despite a recent weak stock market performance. The piece includes key financial …

What is Northland Securities' Estimate for RELL Q1 Earnings?

RICHARDSON ELECTRONICS, LTD. SEC Filing (Jul 28, 2026)

This article reports on an SEC Form 144 filing by Richardson Electronics, Ltd. (REEL) on July 28, 2026. The filing indicates a proposed sale of 10,000 common shares with an aggregate market value of $179,600, acquired via stock option exercise, suggesting an insider transaction. …

RELL (RELL) holder files to sell 10,000 common shares via Fidelity

A shareholder of Richardson Electronics, Ltd. (RELL) has filed a Form 144 notice to sell 10,000 common shares through Fidelity Brokerage Services LLC. The aggregate market value of these shares is $215,000.00, with a proposed sale date of July 28, 2026. The shares were …

Richardson Electronics Raised to Outperform From Market Perform by Northland Capital Markets

Northland Capital Markets has upgraded the rating for Richardson Electronics (RELL) stock from Market Perform to Outperform. This adjustment suggests an increased positive outlook on the company's future performance by the investment bank.

RELL (RELL) investor plans $454,119 sale of stock-award shares

A holder of RICHARDSON ELECTRONICS, LTD. (RELL) common stock, through Fidelity Brokerage Services LLC, plans to sell 23,901 shares valued at $454,119.00 on or about July 28, 2026. These shares originate from stock awards granted as compensation between 2023 and 2025. The Form 144 …

276,100 Shares in Ambarella, Inc. $AMBA Bought by Hawk Ridge Capital Management LP

Hawk Ridge Capital Management LP recently acquired 276,100 shares of Ambarella, Inc. (NASDAQ:AMBA), valued at approximately $14.2 million, adding to the significant institutional ownership of the semiconductor company. While Ambarella remains unprofitable, its latest quarterly results met analyst expectations with EPS of $0.11 and …

Richardson Electronics Ltd (RELL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Richardson Electronics Ltd (RELL), stating its current valuation score is 8.64, ranking 26 out of 60 in the Electronic Equipment & Parts industry. It highlights the company's P/E ratio of 71.08, noting it is significantly below its …

Ambarella Inc (AMBA) Institutional Confidence

Ambarella Inc's institutional shareholding score is 7.00, placing it 45th out of 105 in the Semiconductors & Semiconductor Equipment industry. The institutional shareholding proportion is 86.10%, which is a 12.35% decrease quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 296.20K shares.

Stifel reiterates Buy on Ambarella stock, cites chip roadmap

Stifel reiterated a Buy rating on Ambarella (NASDAQ:AMBA) with a $106 price target, citing a constructive outlook driven by the ramp of its third-generation 5nm CV72/CV75 and 4nm CV7 chips, with the 2nm CV8 expected in early fiscal year 2028. The firm anticipates operating …

Ambarella Inc (AMBA) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a dividend and stock split history for Ambarella Inc (AMBA), noting that the company has not distributed any dividends over the past five years. It presents current stock performance data, including its market cap and recent price movements. The page also …

Estrella Immunopharma Inc (ESLA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Estrella Immunopharma Inc (ESLA). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page displays basic stock information such as market …

Estrella Immunopharma Inc (ESLA) Balance Sheet

This article provides detailed quarterly and annual balance sheet data for Estrella Immunopharma Inc (ESLA), allowing investors to analyze its financial health, liquidity, leverage, and return on equity. The balance sheet includes metrics such as cash and short-term investments, total assets, various liabilities, and …

Sidoti Forecasts Lower Earnings for Richardson Electronics

Estrella Immunopharma Inc (ESLA) Cash Flow - Tradingkey.com

This article provides a detailed cash flow statement for Estrella Immunopharma Inc (ESLA), presenting quarterly and annual financial data for operating, investing, and financing activities. It includes key metrics like operating cash flow, net income, and changes in working capital, along with definitions for …

Richardson Electronics Ltd (RELL) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a detailed historical timeline of dividends and stock splits for Richardson Electronics Ltd (RELL), highlighting payouts over the past five years. It lists ex-dividend, record, and payment dates along with the gross cash dividend amount per share. The company has distributed …

Estrella Immunopharma Inc (ESLA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Estrella Immunopharma Inc (ESLA), listing major individual and institutional holders. It specifies the proportion of shares held by different types of shareholders, including corporations, individual investors, and various investment firms. The report also includes historical institutional shareholding …

Ambarella, Inc. Revenue Breakdown – NASDAQ:AMBA

Ambarella, Inc. (NASDAQ: AMBA) generated $390.70 million in revenue last year, with its Low-power Artificial Intelligence-based Processing and Video and Image Processing System on a Chip Solutions segment being the sole contributor. Taiwan was the largest regional contributor, accounting for $271.93 million of the …

AMBA|Ambarella Inc|Price:81.605|Chg%:-0.355

TradingKey

This article provides a detailed income statement for Estrella Immunopharma Inc. (ESLA), presenting quarterly financial data for operating expenses, R&D expenses, operating profit, various net income metrics, and earnings per share. It also includes an overview of the company's stock performance and an FAQ …

Estrella Immunopharma Inc (ESLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Estrella Immunopharma Inc (ESLA), detailing its performance based on various indicators and moving averages. It covers MACD, RSI, KDJ, and other technical signals, indicating a "Neutral" overall signal. The analysis also explains what technical ratings and moving …

Estrella Immunopharma Inc (ESLA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Estrella Immunopharma Inc (ESLA), detailing various volatility and risk metrics. It covers maximum drawdown, return-to-drawdown ratio, skewness, realized volatility, and liquidity metrics such as average turnover rate. The data presented offers insights into the stock's historical performance …

Estrella Immunopharma Inc (ESLA) Institutional Confidence

This article from TradingKey provides an overview of Estrella Immunopharma Inc.'s (ESLA) institutional confidence. It lists key institutional shareholders, including Eureka Therapeutics Inc., Renaissance Technologies LLC, Geode Capital Management, L.L.C., and Citadel Advisors LLC, along with the number of shares held and the change …

Estrella doses first patient in EB103 trial expansion phase By Investing.com

Estrella Immunopharma Inc. (NASDAQ:ESLA) has announced that the first patient has been dosed in the expansion phase of its STARLIGHT-1 Phase I/II clinical trial for EB103, a CD19-redirected ARTEMIS T-cell therapy. This phase evaluates EB103 in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma, building on …

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma has dosed the first patient in the dose-expansion phase of its STARLIGHT-1 Phase I/II clinical trial for EB103, targeting relapsed/refractory B-cell non-Hodgkin's lymphoma. This milestone follows encouraging efficacy data from the dose-escalation cohort, where all patients who achieved complete response at 6 …

Richardson Electronics (RELL) Stock Faces Lofty P/E As Profitability Recovery Tests Bullish Narrative

Perella Weinberg Partners (PWP) Projected to Release Quarterly Earnings on Friday

Form 4 Richardson Electronics Ltd For: 23 July By Investing.com

This article announces the filing of Form 4 for Richardson Electronics Ltd on July 23, 2026. Form 4 is a document filed with the SEC to report changes in ownership of company stock by insiders. The brief piece simply states the event without providing …

Richardson Electronics (NASDAQ: RELL) CFO surrenders 1,000 shares to cover taxes

Richardson Electronics (NASDAQ: RELL) CFO Ben Robert J surrendered a total of 1,000 common shares on July 21 and 22, 2026, to cover income tax withholding obligations on vested restricted shares. These transactions were reported as share surrenders to the issuer, not open-market sales, …

Richardson Electronics (NASDAQ: RELL) COO uses stock to cover tax withholding

Richardson Electronics (NASDAQ: RELL) COO Wendy Diddell surrendered a total of 5,598 shares of common stock to the company on July 21 and July 22, 2026, to satisfy income tax withholding obligations related to the vesting of previously granted restricted shares. These transactions were …